DSIP vs FOXO4-DRI
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide
DSIP, or delta sleep-inducing peptide, is a small naturally occurring nonapeptide (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in the 1970s from the blood of sleeping rabbits. As the name suggests, it was named for its ability to promote delta-wave (deep, slow-wave) sleep in animals. Despite five decades of study it has no regulatory approval and the human evidence for it as a sleep aid is weak and inconsistent.
Also: FOX04-DRI, FOXO4 D-Retro-Inverso
FOXO4-DRI is an experimental senolytic peptide, meaning it is designed to kill off worn-out 'zombie' cells (senescent cells) while leaving healthy ones alone. It comes from a single influential 2017 mouse study and is engineered with a clever stability trick. It has never been tested in a human clinical trial, so anything beyond 'promising in mice' is speculation.
Key Comparison Insights
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- DSIP has stronger research evidence (Human Trials) compared to FOXO4-DRI (Animal Studies).
Detailed Comparison
| Attribute | DSIP | FOXO4-DRI |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | How DSIP actually works is still not nailed down, which is unusual for a peptide this old. It does not have one clear receptor of its own. Instead it seems to act as a modulator, influencing slow-wave sleep, neurotransmitter levels, circadian rhythm, hormone release (including growth hormone), and stress responses. One striking animal finding: injecting antibodies against DSIP into the brain blocked the normal rise in slow-wave sleep and growth hormone, hinting that the body's own DSIP plays a real regulatory role. Some reports also suggest it can act on opioid-related pathways, which is why it has been studied in addiction withdrawal. Treat these mechanisms as plausible but not fully proven. | Senescent cells should die but don't, partly because the protein FOXO4 holds p53 hostage in the nucleus, keeping the cell's self-destruct program switched off. FOXO4-DRI is a peptide based on a FOXO4 sequence that competes for that interaction, freeing p53 and pushing it out of the nucleus, which triggers p53/p21-dependent apoptosis selectively in senescent cells. The 'DRI' stands for D-retro-inverso: the peptide is built from D-amino acids in reversed order, a design that resists enzyme breakdown and improves stability while preserving the binding shape. The selectivity is the appeal, since healthy proliferating cells are largely spared in the preclinical work. |
| Common Dosing | 100-250 mcg before bed Once daily, 30 min before sleep | 2-10 mg every other day for 3 doses (one cycle) 3 doses every other day, 1-3 cycles per year |
| Administration | Subcutaneous, intramuscular, or intranasal | Subcutaneous injection (community), IV/IP in animal studies |
| Typical Duration | 2-4 weeks typical | 1 cycle = 3 doses over 5-6 days, repeat 1-3x yearly |
| Best Time to Take | 30-60 minutes before bed | Per research protocol |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The early animal work was genuinely interesting: DSIP reliably increased delta sleep in rabbits, rats, and mice, and seemed tied to growth hormone release during sleep. The human data is far less convincing. A few small studies reported longer or better sleep after intravenous DSIP in chronic insomniacs, with no daytime grogginess. But a double-blind, placebo-controlled study published in Neuropsychobiology (1992) concluded that short-term DSIP treatment of chronic insomnia is unlikely to be of major therapeutic benefit, since objective gains were weak and patients did not feel their sleep was better. Separate older reports claimed high success rates relieving opiate and alcohol withdrawal symptoms, but these were small, uncontrolled, and never replicated to modern standards. Bottom line: real history, real animal data, but no solid randomized evidence that it works as a sleep drug in people. | The foundational study (Baar et al., Cell, 2017) reported that FOXO4-DRI selectively pushed senescent cells into apoptosis and, in mice, restored fur density, kidney function, and physical fitness, and helped counteract the toxicity of the chemotherapy drug doxorubicin. That is a striking result and it kicked off real interest in senolytic peptides. A few honest caveats. Some vendor and blog claims, like a specific percent lifespan extension, are not supported by the original paper and appear fabricated. Independent groups have since shown FOXO4-DRI can clear senescent human cells in culture (for example, expanded chondrocytes), and newer peptides report being several-fold more potent. Bottom line: the mouse and in vitro data are interesting, but there are no published human clinical trials, no established safe human dose, and long-term safety is unknown. |
Frequently Asked Questions: DSIP vs FOXO4-DRI
What is the difference between DSIP and FOXO4-DRI?
DSIP is a anti-aging peptide that dsip, or delta sleep-inducing peptide, is a small naturally occurring nonapeptide (sequence trp-ala-gly-gly-asp-ala-ser-gly-glu) first isolated in the 1970s from the blood of sleeping rabbits. as the name suggests, it was named for its ability to promote delta-wave (deep, slow-wave) sleep in animals. despite five decades of study it has no regulatory approval and the human evidence for it as a sleep aid is weak and inconsistent. FOXO4-DRI is a anti-aging peptide that foxo4-dri is an experimental senolytic peptide, meaning it is designed to kill off worn-out 'zombie' cells (senescent cells) while leaving healthy ones alone. it comes from a single influential 2017 mouse study and is engineered with a clever stability trick. it has never been tested in a human clinical trial, so anything beyond 'promising in mice' is speculation. The main differences lie in their mechanisms of action and clinical applications.
Which is better, DSIP or FOXO4-DRI?
Neither is universally "better" - the choice depends on your specific goals. DSIP is typically used for anti-aging purposes, while FOXO4-DRI is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can DSIP and FOXO4-DRI be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using DSIP and FOXO4-DRI together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.